Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb, Exelixis, Extend Oncology Research Collaboration

NEW YORK, Dec. 17 (GenomeWeb News) - Exelixis and Bristol-Myers Squibb Company have extended their oncology research collaboration until December 2006, the companies said today.


The collaboration, originally announced in July 2001, involves discovery of potential drug targets for cancer. Initially, Bristol-Myers made a $20 million equity investment in Exelixis, and a $5 million upfront payment for Exelixis' functional genomics services, followed by $3 million a year for at least three years.


Under this extended deal, the parties have the goal of increasing the number and degree of validation of cancer targets that will be delivered by Bristol-Myers Squibb. Each party will maintain the exclusive worldwide rights to equal numbers of validated targets that stem from the collaboration.


Bristol-Myers Squibb will make an an upfront payment to Exelixis, will increase its annual research funding, and will provide milestones on validated cancer targets. The company will also provide Exelixis milestone payments on compounds that go through regulatory and clinical stages.


The Scan

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.